Thomas Malley Sells 78,233 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• Director Thomas Malley of Kiniksa Pharmaceuticals sold a total of 78,233 shares on August 14 at an average price of $33.09, significantly reducing his ownership in the company by 86.18%.
• Kiniksa reported better-than-expected earnings for the previous quarter, with an EPS of $0.23, surpassing analyst estimates of $0.18, and a revenue of $156.80 million against expectations of $145.21 million.
• The stock of Kiniksa Pharmaceuticals experienced a slight decline of 1.1%, trading at $33.28, and has a market capitalization of $2.47 billion with a P/E ratio of 832.21.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Thomas Malley sold 78,233 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the transaction, the director owned 12,546 shares in the company, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Thomas Malley also recently made the following trade(s):

• On Wednesday, August 13th, Thomas Malley sold 50,129 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.32, for a total transaction of $1,670,298.28.
• On Tuesday, August 12th, Thomas Malley sold 49,407 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $32.40, for a total transaction of $1,600,786.80.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA traded down $0.57 during trading hours on Tuesday, hitting $33.15. The stock had a trading volume of 371,536 shares, compared to its average volume of 712,135. The business's 50 day moving average is $29.49 and its 200-day moving average is $25.23. The company has a market cap of $2.46 billion, a price-to-earnings ratio of 828.96 and a beta of 0.14. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $34.55.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KNSA. Tower Research Capital LLC TRC increased its stake in Kiniksa Pharmaceuticals International by 1,539.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 25,275 shares of the company's stock valued at $699,000 after buying an additional 23,733 shares during the last quarter. Rubric Capital Management LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after buying an additional 526,567 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 428.8% in the 2nd quarter. Lazard Asset Management LLC now owns 15,181 shares of the company's stock valued at $420,000 after acquiring an additional 12,310 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at about $1,640,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company's stock valued at $18,192,000 after acquiring an additional 447,536 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of several recent analyst reports. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Finally, Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.